Pharmac is consulting on a proposal to widen access to, and award principal supply of adalimumab (biosimilar).
We want to hear from people about this proposal which would give more New Zealanders access to adalimumab.
Please share this information
We want to make sure everyone who might be interested is aware of these proposed changes. Please share this information with people you think might want to provide feedback on this consultation.
Details about this proposal
We are proposing to make changes to the funded brand of adalimumab, from Humira to a citrate-free biosimilar called Amgevita. Amgevita is Medsafe registered and is supplied by Amgen in more than 40 countries around the world.
If the proposal is approved, a number of changes would occur. These include:
Submitting your feedback
We welcome and value your feedback on this proposal. Please provide feedback by 5 pm, Wednesday 22 September 2021. Feedback can be submitted using this webform or emailed to firstname.lastname@example.org.
Write something about yourself. No need to be fancy, just an overview.